STOCK TITAN

111 to Announce Third Quarter 2020 Unaudited Financial Results on November 19, 2020

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

SHANGHAI, Oct. 22, 2020 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading digital healthcare platform committed to digitally connecting patients with healthcare products and services in China, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2020, before the U.S. market opens on Thursday, November 19, 2020.

111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Thursday, November 19, 2020 (8:30 PM Beijing Time on the same day).

Details for the conference call are as follows:

Event Title:  

111, Inc. Third Quarter 2020 Earnings Conference Call

Registration Link: 

http://apac.directeventreg.com/registration/event/1679252

All participants must use the link provided above to complete the online registration process in advance of the conference call. Upon registering, each participant will receive a set of participant dial-in numbers, the Direct Event passcode, and a unique Registration ID, which can be used to join the conference call.

Please dial in 15 minutes before the call is scheduled to begin and provide the Direct Event passcode and unique Registration ID you have received upon registering to join the call.

A telephone replay of the call will be available after the conclusion of the conference call until November 27, 2020, 7:59 P.M. ET on:

United States: 

+1-855-452-5696

International: 

+61-2-8199-0299

Conference ID:

1679252

A live and archived webcast of the conference call will be available on the Investor Relations section of 111's website at http://ir.111.com.cn/.

About 111, Inc.

111, Inc. (NASDAQ: YI) ("111" or the "Company") is a leading digital healthcare platform committed to digitally connecting patients with healthcare products and services in China. The Company provides consumers with better access to pharmaceutical products and healthcare services directly through its online retail pharmacy, 1 Drugstore, and indirectly through its offline virtual pharmacy network. The Company also offers online healthcare services through its internet hospital, 1 Clinic, which provides consumers with cost-effective and convenient online consultation, electronic prescription service, and patient management service. In addition, the Company's online wholesale pharmacy, 1 Drug Mall, serves as a one-stop shop for pharmacies to source a vast selection of pharmaceutical products. With the largest virtual pharmacy network in China, 111 enables offline pharmacies to better serve their customers with cloud-based services. 111 also provides an omni-channel drug commercialization platform to its strategic partners, which includes services such as digital marketing, patient education, data analytics, and pricing monitoring.

For more information on 111, please visit: http://ir.111.com.cn/.

For more information, please contact:
111, Inc.
Investor Relations
Email: ir@111.com.cn

111, Inc.
Media Relations 
Email: press@111.com.cn
Phone: +86-021-2053 6666 (China)

GCM Strategic Communications
IR Counsel
Email: 111.ir@gcm.international

 

Cision View original content:http://www.prnewswire.com/news-releases/111-to-announce-third-quarter-2020-unaudited-financial-results-on-november-19-2020-301157775.html

SOURCE 111, Inc.

111, Inc. American Depositary Shares

NASDAQ:YI

YI Rankings

YI Latest News

YI Stock Data

89.45M
65.94M
16.72%
28.28%
0.04%
Pharmacies and Drug Stores
Retail Trade
Link
United States of America
Shanghai

About YI

111, inc., through its subsidiaries, operates an integrated online and offline platform in the healthcare market in the people's republic of china. it operates through two segments, b2b and b2c. the company sells medical and wellness products through online retail, and wholesale and retail pharmacies, as well as provides value-added services, such as online consultation services and e-prescription services to consumers. its product portfolio comprises prescription and over-the counter drugs, such as western and traditional chinese medicinal drugs; nutritional supplements, such as vitamins and dietary products; contact lenses; medical supplies and devices, including bandages and thermometers; and personal care products, such as skin care, birth control, and sexual wellness products; and baby products. the company also operates an online marketplace where third-party sellers can directly sell to pharmacies; provides online loan application services to the clients of 1 drug mall, includin